Rituximab is included because BRUIN CLL-322 uses venetoclax-rituximab as the comparator backbone for previously treated CLL/SLL. In this workbook it should not be confused with obinutuzumab; the BRUIN CLL-322 late-breaking study is pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab. EHA 2026
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
Executive Summary
Rituximab (Rituxan / MabThera) is the chimeric anti-CD20 monoclonal antibody that opened the modern era of B-cell-targeted therapy. Genentech and Idec Pharmaceuticals co-developed the molecule (later partnered with Roche for ex-US). The FDA granted approval on 1997-11-26 for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma, then expanded into diffuse large B-cell lymphoma (R-CHOP), follicular lymphoma, chronic lymphocytic leukemia (FCR, BR), rheumatoid arthritis, ANCA-associated vasculitis, pemphigus vulgaris, and graft-versus-host disease prophylaxis.
Notably, the Patsnap Eureka pharma-intelligence stack returns 372 CD20-targeting drug records, 2,637 CD20-related patents filed since January 2023, and 1,558 active Phase 2 or Phase 3 trials with rituximab as the main investigational drug. Within that pool, three classes of CD20-directed agents now compete: anti-CD20 monoclonal antibodies (rituximab, obinutuzumab, ofatumumab, ocrelizumab, ublituximab, divozilimab, ripertamab, zuberitamab), CD20 × CD3 bispecific antibodies (epcoritamab, glofitamab, mosunetuzumab, odronextamab), and CD19 or CD20 CAR-T or radiolabeled antibody approaches (ibritumomab tiuxetan, IMPT-314, KITE-753, zamtocabtagene autoleucel).
As a result, EHA 2026 frames rituximab in two roles. In BRUIN CLL-322 (LB5001), rituximab is the anti-CD20 component of the venetoclax-rituximab backbone — explicitly not obinutuzumab. Across hematologic malignancies, biosimilar rituximab dominates by volume while next-generation CD20 × CD3 bispecifics push deeper into earlier lines. The strategic question is whether rituximab keeps its combination footprint as biosimilar pricing collapses and bispecifics absorb the high-margin segments.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.
Arena Overview
Rituximab MoA snapshot — Rituximab is a chimeric IgG1 kappa monoclonal antibody that binds the CD20 antigen on the surface of pre-B and mature B-lymphocytes. Crucially, CD20 is not expressed on hematopoietic stem cells or plasma cells. As a result, B-cell depletion preserves the precursor and effector compartments. Multiple effector mechanisms drive efficacy: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptotic signaling.
CD20-targeting field (372 records) — Among CD20-targeting drug records, four architectural classes compete: chimeric or humanized anti-CD20 monoclonal antibodies (rituximab, obinutuzumab, ofatumumab, ocrelizumab, ublituximab, ripertamab, zuberitamab, divozilimab), CD20 × CD3 bispecific T-cell engagers (epcoritamab, glofitamab, mosunetuzumab, odronextamab, TQB-2825), CD19/CD20 CAR-T therapies (zamtocabtagene autoleucel, IMPT-314, KITE-753), and radiolabeled antibodies (ibritumomab tiuxetan, iodine-131 tositumomab). Subcutaneous co-formulations (rituximab/hyaluronidase, 2016) extend the franchise lifecycle.
CD20 patent activity (since 2023) — In addition, assignees have filed 2,637 CD20-related patent families since January 2023. The filings span next-generation Type II anti-CD20 antibodies, CD20 × CD3 bispecific scaffolds, CD20 × CD19 dual-target CAR-T architectures, anti-CD20 antibody-drug conjugates, and Fc-engineered variants with extended half-life or improved ADCC.
Player Summary Table
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Roche / Genentech (Rituxan) | US/CH | T1 (Leader) | Chimeric anti-CD20 mAb | Rituximab (1997-11-26); R-CHOP DLBCL; FCR/BR CLL; venetoclax-rituximab backbone (BRUIN CLL-322) |
| Roche / Genentech (Obinutuzumab) | US/CH | T1 (Next-gen) | Type II glycoengineered anti-CD20 mAb | Obinutuzumab (2013-11-01); CLL14 frontline VenG; DLBCL G-CHOP; obinutuzumab-β approved 2026-02-10 in China |
| Novartis / GSK (Ofatumumab) | UK/CH | T1 (Adjacent) | Fully human anti-CD20 mAb | Ofatumumab (Arzerra/Kesimpta, 2009-10-26); RMS subcutaneous formulation; CLL legacy |
| Roche / Genentech (Ocrelizumab) | US/CH | T1 (MS) | Humanized anti-CD20 mAb | Ocrelizumab (Ocrevus, 2017-03-28); RMS, PPMS; B-cell depletion benchmark in MS |
| TG Therapeutics | US | T2 (Challenger) | Glycoengineered anti-CD20 mAb | Ublituximab (Briumvi, 2022-12-28); RMS; ULTIMATE I/II Phase 3 |
| Biocad / Generium (Divozilimab) | RU | T2 (Regional) | Anti-CD20 mAb | Divozilimab — Russian-developed CD20 mAb for autoimmune indications |
| Sansheng / 3SBio (Ripertamab) | CN | T2 (Regional) | Anti-CD20 mAb | Ripertamab (2022-08-23); China-led NHL; biosimilar-class positioning |
| Bio-Thera Solutions / Sanofi (Zuberitamab) | CN | T2 (Regional) | Anti-CD20 mAb | Zuberitamab (2023-05-12); China NHL approval |
| AbbVie / Genmab (Epcoritamab) | US/DK | T1 (Bispecific challenger) | CD20 × CD3 bispecific (subcutaneous) | Epcoritamab (Epkinly, 2023-05-19); DLBCL relapsed/refractory; EPCORE NHL trials |
Bispecifics, CAR-T, and Watchlist Players
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Roche / Genentech (Glofitamab) | US/CH | T1 (Bispecific challenger) | CD20 × CD3 bispecific (2:1) | Glofitamab (Columvi, 2023-03-24); fixed-duration DLBCL; STARGLO Phase 3 |
| Roche / Genentech (Mosunetuzumab) | US/CH | T1 (Bispecific in FL) | CD20 × CD3 bispecific | Mosunetuzumab (Lunsumio, 2022-06-03); follicular lymphoma after ≥2 prior |
| Regeneron (Odronextamab) | US | T2 (Bispecific challenger) | CD20 × CD3 bispecific | Odronextamab (2024-08-22); FL/DLBCL; ELM-1 / ELM-2 trials |
| Chia Tai Tianqing | CN | T3 (Bispecific follower) | CD20 × CD3 bispecific | TQB-2825 — Phase 1; China-developed bispecific |
| Spectrum (Ibritumomab Tiuxetan) | US | Watchlist | Radiolabeled CD20 antibody | Ibritumomab tiuxetan (Zevalin, 2002); legacy radioimmunotherapy |
| Miltenyi Biotec (Zamtocabtagene autoleucel) | DE | T2 (CAR-T) | CD19/CD20 dual CAR-T | Zamtocabtagene autoleucel — Phase 2/3 DALY-2 trial in DLBCL |
| ImmPACT Bio / Kite Pharma (CD20 CAR-T) | US | Watchlist | Anti-CD20 CAR-T | IMPT-314, KITE-753 — Phase 1 CD19/CD20 dual CAR-T |
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Route Differentiation Analysis
In particular, four therapeutic routes define how rituximab competes across CD20-positive B-cell malignancies and autoimmune disease. Each strength level draws from MCP pipeline records and the published trial evidence.
Route × Player Matrix
| Player | Anti-CD20 mAb (Type I) | Anti-CD20 mAb (Type II) | CD20 × CD3 Bispecific | CD19/CD20 CAR-T | Anti-CD20 Radioimmunotherapy |
|---|---|---|---|---|---|
| Roche / Genentech | Strong — Rituximab (Rituxan) | Strong — Obinutuzumab (Gazyva) | Strong — Glofitamab + Mosunetuzumab | Absent | Absent |
| AbbVie / Genmab | Absent | Absent | Strong — Epcoritamab (subcutaneous) | Absent | Absent |
| Regeneron | Absent | Absent | Moderate — Odronextamab | Absent | Absent |
| Novartis / GSK | Strong — Ofatumumab (Arzerra/Kesimpta) | Absent | Absent | Absent | Absent |
| Roche (MS franchise) | Strong — Ocrelizumab (Ocrevus) | Absent | Absent | Absent | Absent |
| TG Therapeutics | Moderate — Ublituximab (Briumvi) | Absent | Absent | Absent | Absent |
| 3SBio (Ripertamab) / Bio-Thera (Zuberitamab) | Moderate — China-developed mAbs | Absent | Absent | Absent | Absent |
| Chia Tai Tianqing | Absent | Absent | Emerging — TQB-2825 | Absent | Absent |
| Miltenyi Biotec | Absent | Absent | Absent | Strong — Zamtocabtagene autoleucel (CD19/CD20 dual) | Absent |
| ImmPACT Bio / Kite Pharma | Absent | Absent | Absent | Moderate — IMPT-314, KITE-753 | Absent |
| Spectrum Pharmaceuticals (legacy) | Absent | Absent | Absent | Absent | Moderate — Ibritumomab tiuxetan |
| Generic / Biosimilar (Sandoz, Celltrion, Mylan, Pfizer) | Strong — Rituximab biosimilars | Absent | Absent | Absent | Absent |
Route Concentration Observations
- Type I anti-CD20 mAb — Additionally, rituximab anchors this slot but biosimilars now control most of the volume across major markets. Ublituximab and the China-led ripertamab and zuberitamab fragment the regional segments.
- Type II anti-CD20 mAb — Meanwhile, Roche owns this category alone through obinutuzumab. Type II antibodies trigger stronger direct cell death and reduced internalization. Obinutuzumab-β received Chinese approval on 2026-02-10.
- CD20 × CD3 bispecifics — In contrast, three Roche-or-AbbVie bispecifics (glofitamab, mosunetuzumab, epcoritamab) plus Regeneron’s odronextamab redefine relapsed B-cell lymphoma management. Subcutaneous epcoritamab particularly threatens rituximab’s ambulatory niche in DLBCL.
- CD19/CD20 CAR-T — Similarly, dual-target CAR-T platforms (zamtocabtagene autoleucel, IMPT-314, KITE-753) address CD19-loss escape after axi-cel and tisa-cel. They sit in third-line+ DLBCL today but creep into earlier settings.
- Combination anchor — Furthermore, rituximab’s defining role is as combination partner. R-CHOP (DLBCL), BR/FCR (CLL), R-bendamustine (FL), and venetoclax-rituximab (BRUIN CLL-322) all rely on rituximab as the CD20 component. Switching to obinutuzumab in those backbones (G-CHOP, VenG) requires an outcome-based justification.
Top Player Deep Dives
1. Roche / Genentech (Tier 1 — CD20 franchise leader)
Primary route: Anti-CD20 monoclonal antibodies (Type I and Type II) plus CD20 × CD3 bispecifics — the broadest CD20-directed franchise.
Key products: Rituximab (Rituxan/MabThera, 1997-11-26); Obinutuzumab (Gazyva, 2013-11-01); Ocrelizumab (Ocrevus, 2017-03-28); Mosunetuzumab (Lunsumio, 2022-06-03); Glofitamab (Columvi, 2023-03-24); Rituximab/Hyaluronidase subcutaneous (2016-11-22); Obinutuzumab-β (China, 2026-02-10).
Differentiation: Notably, Roche covers every CD20 architecture except CAR-T. The Type II glycoengineered design of obinutuzumab improves direct cell death and ADCC. Glofitamab uses a 2:1 CD20:CD3 binding format that drives robust T-cell engagement.
Trajectory: Moreover, Roche cycles patients across rituximab → obinutuzumab → glofitamab/mosunetuzumab as disease progresses. The subcutaneous rituximab co-formulation extends the franchise even after biosimilar entry.
Key risk: However, biosimilar rituximab compresses pricing in DLBCL, FL, and CLL combinations. Bispecifics (glofitamab, mosunetuzumab) cannibalize Roche’s own rituximab volume in relapsed settings.
Roche CD20 Generational Comparison
| Asset | Generation | Format | Approval | Lead Indication |
|---|---|---|---|---|
| Rituximab | 1st chimeric | IgG1 | 1997-11-26 | NHL, CLL, RA, AAV |
| Obinutuzumab | Type II glycoengineered | Humanized IgG1 | 2013-11-01 | CLL frontline (CLL14), FL, DLBCL |
| Ocrelizumab | Humanized Type I | IgG1 | 2017-03-28 | RMS, PPMS |
| Mosunetuzumab | CD20 × CD3 bispecific | 1:1 IgG-like | 2022-06-03 | Relapsed/refractory FL |
| Glofitamab | CD20 × CD3 bispecific | 2:1 IgG | 2023-03-24 | Relapsed/refractory DLBCL |
2. AbbVie / Genmab — Epcoritamab (Tier 1 — Subcutaneous bispecific)
Primary route: Subcutaneous CD20 × CD3 bispecific antibody.
Key product: Epcoritamab (Epkinly, 2023-05-19) — first FDA-approved subcutaneous CD20 bispecific for relapsed/refractory DLBCL after two or more lines. EPCORE NHL-1 and EPCORE NHL-2 evaluate combinations with R-CHOP and other chemotherapy backbones.
Differentiation: Specifically, subcutaneous administration enables outpatient use without infusion centers. As a result, epcoritamab compresses the traditional IV rituximab logistics advantage.
Trajectory: In addition, EPCORE-FL frontline data could move epcoritamab into earlier-line follicular lymphoma. The franchise threatens both rituximab combinations and Roche’s own glofitamab.
Key risk: However, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome management remain the structural barriers to broad outpatient use.
3. Novartis / GSK — Ofatumumab (Tier 1 — Adjacent)
Primary route: Fully human anti-CD20 mAb.
Key product: Ofatumumab (Arzerra for CLL, 2009; Kesimpta for relapsing MS subcutaneous self-administered, 2020). Novartis acquired the MS rights from GSK and reformulated for monthly subcutaneous use.
Differentiation: Notably, Kesimpta’s at-home self-administered subcutaneous design contrasts with hospital-infused ocrelizumab. As a result, Novartis competes head-on with Roche in MS without an infusion footprint.
Trajectory: Furthermore, Kesimpta’s relapsing MS uptake validates subcutaneous CD20 targeting outside oncology.
Key risk: However, Arzerra’s CLL franchise has waned as venetoclax-based regimens take over. Ublituximab competes in MS.
4. TG Therapeutics — Ublituximab (Tier 2 — Glycoengineered challenger)
Primary route: Glycoengineered anti-CD20 mAb.
Key product: Ublituximab (Briumvi, 2022-12-28) — approved for relapsing forms of multiple sclerosis based on ULTIMATE I/II Phase 3.
Differentiation: Specifically, ublituximab uses a faster one-hour IV infusion compared with longer ocrelizumab schedules. The Fc engineering improves ADCC.
Trajectory: In particular, TG Therapeutics positions ublituximab on infusion-time convenience to gain MS share against Roche’s ocrelizumab.
Key risk: However, Kesimpta’s at-home self-administered model still beats any IV infusion on patient convenience.
5. Regeneron — Odronextamab (Tier 2 — Bispecific challenger)
Primary route: CD20 × CD3 bispecific antibody.
Key product: Odronextamab (2024-08-22) — approved in EU for relapsed/refractory follicular lymphoma and DLBCL based on ELM-1 and ELM-2 trials. FDA review ongoing.
Differentiation: Moreover, Regeneron uses a step-up dosing schedule and IV administration. The asset competes directly with Roche’s mosunetuzumab and glofitamab plus AbbVie’s epcoritamab.
Trajectory: Furthermore, Regeneron pairs odronextamab with its anti-CTLA4 and anti-PD-1 portfolio for hematology + immuno-oncology combination experiments.
Key risk: However, four CD20 × CD3 bispecifics now compete in the same FL/DLBCL setting. Pricing and outpatient ergonomics decide adoption.
6. Biosimilar Manufacturers (Tier 1 — Volume)
Primary route: Rituximab biosimilars.
Key suppliers: Sandoz (Rixathon/Riximyo), Celltrion (Truxima), Mylan/Biocon (Riabni), Pfizer (Ruxience), Amgen, Dr. Reddy’s, and 30+ regional manufacturers. As a result, 44 active organizations show up in the rituximab MCP record.
Differentiation: Specifically, biosimilars compete on price (typically 30-50% below the originator). Combinations such as R-CHOP and venetoclax-rituximab now use biosimilar rituximab in most markets.
Trajectory: Furthermore, biosimilar erosion frees originator R&D budget for next-generation modalities while preserving combination volume.
Key risk: However, supply chain disruption and quality recalls have hit biosimilars in 2024-2026. Bispecifics also threaten the entire rituximab combination role independent of who makes the molecule.
BD Deals & Strategic Moves
Key business development activity shaping the rituximab competitive landscape:
| Date | Deal | Parties | Type | Significance |
|---|---|---|---|---|
| 1997-11 | Rituximab FDA approval | Genentech / Idec / Roche | Regulatory | First anti-CD20 mAb for low-grade NHL; opened B-cell-targeted therapy era |
| 2009-10 | Ofatumumab approval (Arzerra) | GSK / Genmab | Regulatory | Second-generation fully human anti-CD20 mAb for CLL |
| 2013-11 | Obinutuzumab approval (Gazyva) | Roche | Regulatory | First Type II glycoengineered anti-CD20; CLL14 frontline VenG |
| 2016-11 | Rituximab/Hyaluronidase (Rituxan Hycela) approval | Roche / Halozyme | Regulatory | Subcutaneous co-formulation extends franchise lifecycle |
| 2017-03 | Ocrelizumab approval (Ocrevus) | Roche / Genentech | Regulatory | First anti-CD20 mAb approved for primary progressive MS |
| 2019 | Rituximab biosimilar wave (Truxima, Ruxience, Riabni, Rixathon) | Celltrion, Pfizer, Amgen, Sandoz | Regulatory | Biosimilar erosion of US rituximab pricing; 30-50% discount |
| 2020-08 | Ofatumumab subcutaneous reformulation (Kesimpta) for RMS | Novartis | Regulatory | At-home self-administered subcutaneous CD20 mAb in MS |
| 2022-06 | Mosunetuzumab approval (Lunsumio) | Roche | Regulatory | First Roche CD20 × CD3 bispecific in relapsed/refractory FL |
| 2022-12 | Ublituximab approval (Briumvi) | TG Therapeutics | Regulatory | Glycoengineered anti-CD20 mAb in MS; one-hour infusion |
| 2023-03 / 2023-05 | Glofitamab + Epcoritamab approvals | Roche + AbbVie/Genmab | Regulatory | Dual CD20 × CD3 bispecific approvals reset DLBCL relapsed/refractory standard |
| 2024-08 | Odronextamab approval | Regeneron | Regulatory (EU) | Fourth CD20 × CD3 bispecific; FL/DLBCL footprint |
| 2026-02 | Obinutuzumab-β approval in China | Local manufacturer | Regulatory | Type II CD20 mAb expansion in China; threatens originator obinutuzumab share |
| 2024-2026 | BRUIN CLL-322 active | Eli Lilly + Roche/Genentech | Pivotal trial | EHA 2026 LB5001 — pirtobrutinib + venetoclax + rituximab vs venetoclax + rituximab |
Strategic Pattern
Strategic pattern: Overall, the rituximab BD theme is franchise migration. Roche has cycled the same patient population through rituximab → obinutuzumab → glofitamab/mosunetuzumab to capture progression-line revenue without losing share to challengers. Meanwhile, AbbVie/Genmab’s epcoritamab and Regeneron’s odronextamab compress the bispecific window, and biosimilar manufacturers absorb commodity rituximab volume. The outcome looks like the AbbVie Humira playbook: originator pricing erodes while next-generation modalities defend the franchise margin elsewhere. EHA 2026 BRUIN CLL-322 keeps rituximab inside the venetoclax combination — but the next BRUIN-class trial may swap to obinutuzumab or to a bispecific entirely.
Unmet Needs & White Spaces
Notably, three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path:
| White Space | Current Coverage | Technical Value | Entry Path |
|---|---|---|---|
| CD20-loss escape salvage (regimens for B-cell lymphoma that loses CD20 expression after rituximab or bispecific exposure) | Sparse — CD19/CD20 dual CAR-T (zamtocabtagene autoleucel, IMPT-314, KITE-753) cover this need only in third-line+ DLBCL; no Phase 3 standard exists | High — addresses the dominant resistance mechanism after rituximab and CD20 bispecific exposure | Phase 2/3 of CD19/CD20 dual CAR-T in second-line; switch-target ADCs (anti-CD79b, anti-CD22) paired with chemotherapy; pre-emptive biomarker testing for CD20 loss |
| At-home subcutaneous CD20 in oncology (subcutaneous rituximab or epcoritamab for community-oncology administration) | Moderate — Rituximab/Hyaluronidase is approved but limited; Kesimpta validates the subcutaneous CD20 model in MS; Epcoritamab is the first SC bispecific in oncology | High — outpatient administration reduces hospitalization burden and broadens community-oncology access | Pragmatic Phase 3 of SC rituximab vs IV; SC epcoritamab + lenalidomide in FL; community-oncology infrastructure trials |
| Anti-CD20 ADC for relapsed B-cell lymphoma (cytotoxic-payload conjugated anti-CD20 antibody) | Sparse — MRG-001 and similar candidates in early-clinical; no approved anti-CD20 ADC; CD79b-targeted polatuzumab is the closest competitor | High — adds direct cytotoxic effect to CD20 binding without T-cell engagement risk | Phase 1/2 of anti-CD20 ADCs in DLBCL; combination with R-CHOP backbone; payload diversification (auristatin, calicheamicin, topoisomerase) |
Risks and Strategic Outlook for 2026 and Beyond
Key Risks
- Biosimilar pricing erosion: However, four major rituximab biosimilars compete in the US and EU, plus 30+ regional generics. Originator pricing has dropped 30-50%, and combinations now default to biosimilar rituximab.
- CD20 × CD3 bispecific displacement: Moreover, glofitamab, mosunetuzumab, epcoritamab, and odronextamab all approve into relapsed/refractory FL or DLBCL. As they push into earlier lines, rituximab combinations compress to first-line settings only.
- CD20-loss escape: Notably, 30-40% of relapsed B-cell lymphomas show reduced CD20 expression after prolonged rituximab exposure. Type II antibodies (obinutuzumab) and CD19/CD20 dual CAR-T address this only partially.
- Regional fragmentation: Furthermore, China-developed anti-CD20 mAbs (ripertamab, zuberitamab) and obinutuzumab-β capture local share without crossing into US/EU markets. Originator volume in Asia drops faster than US.
Strategic Outlook
For strategic planning, the safest near-term bet around rituximab is combination preservation — keeping rituximab inside R-CHOP, BR, FCR, and venetoclax-rituximab regimens while biosimilar pricing absorbs the commodity erosion. However, the highest-upside, highest-risk bets are in CD20 × CD3 bispecifics moving into first-line and CD19/CD20 dual CAR-T platforms that handle CD20-loss escape. White-space opportunities exist in subcutaneous CD20 administration for community oncology and in anti-CD20 ADCs that pair cytotoxic payloads with the established CD20 binding handle. The next two years of rituximab economics will depend less on the molecule itself and more on whether bispecifics absorb the high-margin segments before R-CHOP-class regimens fully migrate to obinutuzumab or to a bispecific anchor.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
